Proc K, Madej M, Wiland P, Sebastian A
Reumatologia. 2023; 61(3):213-218.
PMID: 37522143
PMC: 10373170.
DOI: 10.5114/reum/167472.
Du L, Tang L, Xiao L, Tang K, Zeng Z, Liang Y
Immun Inflamm Dis. 2023; 11(5):e847.
PMID: 37249291
PMC: 10170305.
DOI: 10.1002/iid3.847.
Iwamoto N, Furukawa K, Endo Y, Shimizu T, Sumiyoshi R, Umeda M
Int J Mol Sci. 2021; 22(21).
PMID: 34768991
PMC: 8584010.
DOI: 10.3390/ijms222111561.
Lee K, Achuthan A, Hamilton J
Immunotargets Ther. 2020; 9:225-240.
PMID: 33150139
PMC: 7605919.
DOI: 10.2147/ITT.S262566.
Zhan Y, Lew A, Chopin M
Front Immunol. 2019; 10:2679.
PMID: 31803190
PMC: 6873328.
DOI: 10.3389/fimmu.2019.02679.
GM-CSF in inflammation.
Hamilton J
J Exp Med. 2019; 217(1).
PMID: 31611249
PMC: 7037240.
DOI: 10.1084/jem.20190945.
Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects.
Crotti C, Agape E, Becciolini A, Biggioggero M, Favalli E
Drugs. 2019; 79(16):1741-1755.
PMID: 31486005
DOI: 10.1007/s40265-019-01192-z.
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy....
Taylor P, Saurigny D, Vencovsky J, Takeuchi T, Nakamura T, Matsievskaia G
Arthritis Res Ther. 2019; 21(1):101.
PMID: 30999929
PMC: 6471864.
DOI: 10.1186/s13075-019-1879-x.
GM-CSF as a therapeutic target in autoimmune diseases.
Shiomi A, Usui T, Mimori T
Inflamm Regen. 2017; 36:8.
PMID: 29259681
PMC: 5725926.
DOI: 10.1186/s41232-016-0014-5.
Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.
Grant S, Heel R
Drugs. 2017; 43(4):516-560.
PMID: 28421558
DOI: 10.2165/00003495-199243040-00008.
Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.
Huizinga T, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D
Arthritis Res Ther. 2017; 19(1):53.
PMID: 28274253
PMC: 5343373.
DOI: 10.1186/s13075-017-1267-3.
Selected cytokine pathways in rheumatoid arthritis.
Noack M, Miossec P
Semin Immunopathol. 2017; 39(4):365-383.
PMID: 28213794
DOI: 10.1007/s00281-017-0619-z.
Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date.
Crotti C, Raimondo M, Becciolini A, Biggioggero M, Favalli E
Drug Des Devel Ther. 2017; 11:211-223.
PMID: 28144129
PMC: 5245809.
DOI: 10.2147/DDDT.S104233.
Targeting GM-CSF in inflammatory diseases.
Wicks I, Roberts A
Nat Rev Rheumatol. 2015; 12(1):37-48.
PMID: 26633290
DOI: 10.1038/nrrheum.2015.161.
Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine.
Huang C, Kuo K, Cheng T, Chuang C, Kao C, Hsieh Y
PLoS One. 2015; 10(7):e0133470.
PMID: 26186692
PMC: 4506079.
DOI: 10.1371/journal.pone.0133470.
GM-CSF: An immune modulatory cytokine that can suppress autoimmunity.
Bhattacharya P, Thiruppathi M, Elshabrawy H, Alharshawi K, Kumar P, Prabhakar B
Cytokine. 2015; 75(2):261-71.
PMID: 26113402
PMC: 4553090.
DOI: 10.1016/j.cyto.2015.05.030.
Pivotal roles of GM-CSF in autoimmunity and inflammation.
Shiomi A, Usui T
Mediators Inflamm. 2015; 2015:568543.
PMID: 25838639
PMC: 4370199.
DOI: 10.1155/2015/568543.
Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis.
Greven D, Cohen E, Gerlag D, Campbell J, Woods J, Davis N
Ann Rheum Dis. 2014; 74(10):1924-30.
PMID: 24936585
PMC: 4602263.
DOI: 10.1136/annrheumdis-2014-205234.
Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis.
Di Franco M, Gerardi M, Lucchino B, Conti F
Core Evid. 2014; 9:41-8.
PMID: 24648832
PMC: 3958547.
DOI: 10.2147/CE.S39770.
MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.
Behrens F, Tak P, Ostergaard M, Stoilov R, Wiland P, Huizinga T
Ann Rheum Dis. 2014; 74(6):1058-64.
PMID: 24534756
PMC: 4431325.
DOI: 10.1136/annrheumdis-2013-204816.
